Now in its 10th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies.
The program will be dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year’s conference will focus on commercialization aspects of the field, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.
Leaders from the international community of will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.
The overall format for IC3D 2011 has changed to emphasize products and their development.
Day 1: The Widening Biologic Spectrum will focus on clinical trials, basic and molecular strategies and commercial development of:
Autologous cell products
Allogeneic cells, hybrid preparations, and specialty products
Molecular interventions: Macro and micro Agents
Day 2: Stem Cell Voyages: Pathways to Success in Cardiovascular Diseases
Delivery methods and imaging
Selection of biologics and methodologies in the development of the next generation of clinical trials
By the end of this course, participants should be able to:
Understand the scientific basis for cell-based therapies
Describe new data regarding the capacity of specific cell lineages for cardiac repair
Be familiar with results of clinical studies and the status of large-scale efficacy trials
Appreciate the developmental strategies of next-generation cells, engineered tissue, and their expected first-in-human uses
Appreciate the status of cardiovascular stem cell science at the global level, including development of resources, industry activities, strategies for collaboration, and current applicable policies
This conference is designed for clinicians and clinical investigators, interventional cardiologists, noninvasive cardiologists, cardiac surgeons, research associates, basic science investigators (cell and molecular biologists), members of public and private funding organizations, hospital administrators, program directors, legislators, and regulatory agency personnel.
The program agenda will be posted soon on the website.